Coming Soon
Understand family history of uterine cancer and its implications for clinical documentation and medical coding. Learn about genetic predisposition to uterine cancer, hereditary uterine cancer risk, and relevant healthcare considerations. This resource provides information for accurate medical coding and documentation related to a family history of uterine cancer.
Also known as
Persons with potential health hazards
Relates to family history of various diseases, including cancer.
Malignant neoplasm of female genital organs
Covers uterine cancer diagnoses, relevant for family history context.
Genetic susceptibility to malignant neoplasm
Indicates a genetic predisposition to cancer, applicable to uterine cancer.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the patient being treated for uterine cancer?
When to use each related code
| Description |
|---|
| Family history of uterine cancer |
| Lynch syndrome (HNPCC) |
| Li-Fraumeni syndrome |
Coding F81.9 (Family history of other specified disorders) without sufficient documentation of specific uterine cancer type in the family history may lead to claim denials.
Incorrectly coding a personal history of uterine cancer (C54.x) instead of the family history (F81.9, Z80.4) can cause coding errors and affect risk adjustment.
Missing or inadequate documentation of the family history of uterine cancer can lead to coding queries, rejected claims, and compliance issues.
Q: How does a strong family history of uterine cancer, specifically endometrial cancer, influence my patient's risk stratification and management decisions?
A: A strong family history of uterine cancer, particularly endometrial cancer, significantly increases a patient's risk, especially if multiple first-degree relatives (mother, sister, daughter) are affected or if diagnoses occurred at younger ages. This elevated risk impacts management decisions. Explore how integrating genetic testing, such as for Lynch syndrome (hereditary nonpolyposis colorectal cancer or HNPCC), can clarify the inherited risk and guide personalized screening and preventive strategies like more frequent endometrial biopsies or even risk-reducing hysterectomy. Consider implementing risk-reducing strategies earlier based on family history even if genetic testing is negative, as some familial risks are not yet explained by known genetic mutations. Explore current NCI guidelines for uterine cancer screening in high-risk individuals.
Q: What are the key genetic syndromes associated with an increased risk of uterine cancer that I should consider in my differential diagnosis?
A: Several genetic syndromes increase the risk of uterine or endometrial cancer. Lynch syndrome (HNPCC) is the most common and is linked to mutations in DNA mismatch repair genes. Other syndromes include Cowden syndrome (PTEN mutations), Li-Fraumeni syndrome (TP53 mutations), and Constitutional Mismatch Repair Deficiency (CMMRD). Learn more about the specific gene mutations associated with each syndrome and their implications for uterine cancer risk. Consider implementing a detailed family history assessment to identify potential red flags suggesting these syndromes, such as early-onset cancers, multiple primary cancers, or specific tumor types within the family. Genetic counseling and testing are crucial for confirming a diagnosis and informing appropriate screening and management protocols for these hereditary cancer syndromes.
Patient presents with concerns regarding family history of uterine cancer, specifically mentioning [relationship to affected relative(s)] diagnosed with [specific type of uterine cancer, e.g., endometrial adenocarcinoma, uterine sarcoma] at age [age of diagnosis]. This raises the possibility of a genetic predisposition to uterine cancer, increasing her risk for developing the disease. Patient reports [symptoms if present, e.g., abnormal vaginal bleeding, pelvic pain, postmenopausal bleeding], or denies any current symptoms. Relevant medical history includes [list relevant medical history, e.g., nulliparity, obesity, diabetes, hypertension, use of tamoxifen, history of PCOS]. Family history is significant for [detailed family history of cancer including affected relatives, type of cancer, and age of diagnosis]. Physical examination revealed [relevant findings, e.g., normal pelvic exam, enlarged uterus]. Assessment includes genetic predisposition to uterine cancer, also known as hereditary uterine cancer risk. Differential diagnosis includes other causes of abnormal uterine bleeding, such as endometrial hyperplasia, polyps, and fibroids. Plan includes discussion of genetic counseling and testing options, such as Lynch syndrome screening, to assess inherited cancer risk. Patient education provided on risk factors for uterine cancer, early detection strategies, and potential prophylactic measures, including increased surveillance and risk-reducing surgery. Follow-up scheduled for [date] to discuss genetic testing results and develop a personalized risk management plan based on her individual risk profile and preferences. ICD-10 code Z80.3 (family history of malignant neoplasm of uterus) is documented.